N4 Pharma PLC Posting of Annual Report & Notice of AGM (3566S)

TIDMN4P

RNS Number : 3566S

N4 Pharma PLC

09 March 2023

9 March 2023

N4 Pharma plc

("N4 Pharma" or the "Company")

Posting of Annual Report & Notice of AGM

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, announces that its Annual Report and Accounts for the year ended 31 December 2022 and Notice of its Annual General Meeting ("AGM") has been posted to shareholders.

The AGM will be held at 11.00 a.m. on 3 April 2023 at Shakespeare Martineau LLP, 6th Floor 60 Gracechurch Street, London, EC3V 0HR.

The Group's Annual Report and Accounts and the Notice of AGM will be made available on the Company's website: https://www.n4pharma.com/

Enquiries:

 
 N4 Pharma plc 
 Nigel Theobald, CEO                           Via IFC Advisory 
 Luke Cairns, Executive Director 
 
 SP Angel Corporate Finance LLP                Tel: +44(0)20 3470 
                                                0470 
 Nominated Adviser and Joint Broker 
 Matthew Johnson/Kasia Brzozowska (Corporate 
  Finance) 
 Vadim Alexandre/Abigail Wayne/Rob Rees 
  (Corporate Broking) 
 
 Turner Pope Investments (TPI) Limited         Tel: +44(0)20 3657 
                                                0050 
 Joint Broker 
 Andy Thacker 
  James Pope 
 
 IFC Advisory Ltd                              Tel: +44(0)20 3934 
                                                6630 
 Financial PR 
 Graham Herring 
 Zach Cohen

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec(R).

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through preclinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOASSEFWAEDSELD

(END) Dow Jones Newswires

March 09, 2023 02:00 ET (07:00 GMT)

N4 Pharma (AQSE:N4P.GB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024